1. TGFβ pathway inhibition in the treatment of non-small cell lung cancer
   Pınar Ö. Eser et al, 2017, Pharmacology & Therapeutics CrossRef
2. Targeting EGFR in Lung Cancer: Current Standards and Developments
   Asunción Díaz-Serrano et al, 2018, Drugs CrossRef
3. Clinical impact of rare and compound mutations of epidermal growth factor receptor in patients with non-small cell lung cancer
   Juliane Büttner et al, 2019, Clinical Lung Cancer CrossRef
4. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)
   Ping-Chih Hsu et al, 2019, IJMS CrossRef
5. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors
   Lih-Chyun Chang et al, 2019, European Journal of Cancer CrossRef
6. Potential mechanism of primary resistance to icotinib in patients with advanced non–small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi‐center study
   Lei Lei et al, 2020, Cancer Sci CrossRef
7. Actionable Mutation Profiles of Non-Small Cell Lung Cancer patients from Vietnamese population
   Anh-Thu Huynh Dang et al, 2020, Sci Rep CrossRef
8. A novel EGFR-TKI inhibitor (cAMP-H3BO3complex) combined with thermal therapy is a promising strategy to improve lung cancer treatment outcomes
   Yongpeng Tong et al, 2017, Oncotarget CrossRef
9. The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC).
   Ping-Chih Hsu et al, 2020, Cancers (Basel) CrossRef
10. Successful treatment of a patient with NSCLC carrying uncommon compound EGFR G719X and S768I mutations using osimertinib: A case report
    Yangyang Cai et al, 2020, J Int Med Res CrossRef
11. Cancer cell‑specific anticancer effects of Coptis�chinensis on gefitinib‑resistant lung cancer cells are mediated through the suppression of Mcl‑1 and Bcl‑2
    Jae Hwan Kim et al, 2020, Int J Oncol CrossRef
12. Identification of RFC5 as a novel potential prognostic biomarker in lung cancer through bioinformatics analysis
    Meng Wang et al, 2018, Oncol Lett CrossRef
13. Advances in targeting EGFR allosteric site as anti-NSCLC therapy to overcome the drug resistance
    Swastika Maity et al, 2020, Pharmacol. Rep CrossRef
14. Challenges and Opportunities in Cancer Drug Resistance
    Richard A. Ward et al, 2020, Chem. Rev. CrossRef
15. Making NSCLC Crystal Clear: How Kinase Structures Revolutionized Lung Cancer Treatment
    Juliana F. Vilachã et al, 2020, Crystals CrossRef
16. Non-invasive detection of EGFR mutations by cell-free loop-mediated isothermal amplification (CF-LAMP)
    Srividya Arjuna et al, 2020, Sci Rep CrossRef
17. The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study
    Ping-Chih Hsu et al, 2020, Pharmaceuticals CrossRef
18. BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer
    Fushun Fan et al, 2021, Translational Oncology CrossRef
19. Routine Molecular Screening of Patients with Advanced Non-SmallCell Lung Cancer in Circulating Cell-Free DNA at Diagnosis and During Progression Using OncoBEAMTM EGFR V2 and NGS Technologies
    Jessica Garcia et al, 2021, Mol Diagn Ther CrossRef
20. Repeated treatment with gefitinib and alectinib in a patient with multiple EGFR-mutant and ALK-mutant lung adenocarcinomas: A case report
    Takafumi Yorozuya et al, 2021, Respiratory Medicine Case Reports CrossRef
21. Bronchial Washing Fluid Versus Plasma and Bronchoscopy Biopsy Samples for Detecting Epidermal Growth Factor Receptor Mutation Status in Lung Cancer
    Xinyu Zhang et al, 2021, Front. Oncol. CrossRef
22. Quantitative analysis of cell-free DNA by droplet digital PCR reveals the presence of EGFR mutations in non-malignant lung pathologies
    Rajesh Venkataram et al, 2021, Monaldi Arch Chest Dis CrossRef
23. Fighting tertiary mutations in EGFR-driven lung-cancers: Current advances and future perspectives in medicinal chemistry
    Laura Scalvini et al, 2021, Biochemical Pharmacology CrossRef
24. Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFRT790M-Mutant NSCLC
    Ha-Ram Park et al, 2021, Journal of Thoracic Oncology CrossRef
25. Machine Learning-Based Radiomics Signatures for EGFR and KRAS Mutations Prediction in Non-Small-Cell Lung Cancer
    Nguyen Quoc Khanh Le et al, 2021, IJMS CrossRef
26. Irradiation Mediates IFNα and CXCL9 Expression in Non-Small Cell Lung Cancer to Stimulate CD8+ T Cells Activity and Migration toward Tumors
    Chun-Chia Cheng et al, 2021, Biomedicines CrossRef
27. A rotamer relay information system in the epidermal growth factor receptor–drug complexes reveals clues to new paradigm in protein conformational change
    Tareq Hameduh et al, 2021, Computational and Structural Biotechnology Journal CrossRef
28. Afatinib treatment in a large real‐world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation
    Chi‐Hsien Huang et al, 2021, Int. J. Cancer CrossRef
29. ELF3 Is a Target That Promotes Therapeutic Efficiency in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer Cells via Inhibiting PKCί
    Jeon-Soo Lee et al, 2021, IJMS CrossRef
30. Long-term survival in a patient with advanced lung adenocarcinoma harboring synchronous EGFR exon 18 G719A and BRAF V600E mutations and treated with afatinib: a case report
    Qing Huang et al, 2022 CrossRef
31. Mutation patterns of epidermal growth factor receptor gene in non-small cell lung cancer among Egyptian patients
    Wafaa H. Elmetnawy et al, 2022, Egyptian Journal of Basic and Applied Sciences CrossRef
32. Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors
    Tyler S. Beyett et al, 2022, Nat Commun CrossRef
33. Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
    Soei Gen et al, 2022, BMC Cancer CrossRef
34. Multicenter Evaluation of the Fully Automated PCR-Based Idylla EGFR Mutation Assay on Formalin-Fixed, Paraffin-Embedded Tissue of Human Lung Cancer
    Solène M. Evrard et al, 2019, The Journal of Molecular Diagnostics CrossRef
35. Association between squamous cell carcinoma antigen level and EGFR mutation status in Chinese lung adenocarcinoma patients
    Shuying Zhang et al, 2022, Clinical Laboratory Analysis CrossRef
36. Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study
    Suey-Haur Lee et al, 2022, Ther Adv Med Oncol CrossRef
37. EGFR mutant status and tyrosine-kinase inhibitors affect the GKRS outcomes for NSCLC brain metastases
    Hung-Ruei Liao et al, 2022, J Neurooncol CrossRef
38. Effective treatment with icotinib in advanced lung adenocarcinoma harboring rare EGFR mutation G719A/L833V: A case report
    Bin Zhou et al, 2022 CrossRef
39. Detection of clinically-relevant EGFR variations in de novo small cell lung carcinoma by droplet digital PCR
    Rajesh Venkataram et al, 2022, Monaldi Arch Chest Dis CrossRef
40. The comparison of cancer gene mutation frequencies in Chinese and U.S. patient populations
    Fayang Ma et al, 2022, Nat Commun CrossRef
41. Impact of GTF2H1 and RAD54L2 polymorphisms on the risk of lung cancer in the Chinese Han population
    Tingting Geng et al, 2022, BMC Cancer CrossRef
42. The mechanism of action of different generations of EGFR-inhibitors in malignant lung tumors. Literature review and data synthesis
    Ainur F. Nasretdinov et al, 2022, J. Mod. Onco. CrossRef
43. Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan
    Ping-Chih Hsu et al, 2023, Targ Oncol CrossRef
44. Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer
    Yufeng Li et al, 2023, Cell Commun Signal CrossRef
45. Investigation of therapeutic modalities of G719X, an uncommon mutation in the EGFR gene in non-small cell lung cancer
    Hua Zheng et al, 2019 CrossRef
46. Natural Product-Based Glycolysis Inhibitors as a Therapeutic Strategy for Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer
    Wonyoung Park et al, 2024, IJMS CrossRef
47. Combining Network Pharmacology, Molecular Docking and Preliminary Experiments to Explore the Mechanism of Action of FZKA Formula on Non-small Cell Lung Cancer
    Zhuixing Liu et al, 2023, PPL CrossRef
48. Current management of uncommon EGFR mutations in non-small cell lung cancer
    Jonathan Q. Trinh et al, 2024, Current Problems in Cancer CrossRef
49. Variant Analysis of miRNA Regulatory Genes in 35 Sporadic Lung Carcinoma Tumors
    Özkan Bağcı et al, 2024, Dokl Biochem Biophys CrossRef
50. In Vitro Modeling of Recurrent Dermatofibrosarcoma Protuberans: Assessment of 5-Aminolevulinic Acid Photodynamic Therapy Efficacy
    Hao Jiang et al, 2024, Photodiagnosis and Photodynamic Therapy CrossRef
51. Detection of EGFR exon 20 insertion mutations in non-small cell lung cancer: implications for consistent nomenclature in precision medicine
    Jieun Park et al, 2024, Pathology CrossRef
52. Weekly Afatinib in the Treatment of Advanced Non-small Cell Lung Cancer with Egfr-G719c Mutation Followed by Lobectomy: A Case Report
    Dung Xuan Ho et al, 2024, Int J Cancer Manag CrossRef
53. Potential roles of tumor microenvironment in gefitinib-resistant non-small cell lung cancer: A narrative review
    Mu-Tong Chen et al, 2023 CrossRef
54. Osimertinib treatment response in a patient with lung adenocarcinoma harboring two rare EGFR mutations: A case report
    Yawen Luo et al, 2024, Oncol Lett CrossRef
55. Effects of Glutamine or Glucose Deprivation on Inflammation and Tight Junction Disruption in Yak Rumen Epithelial Cells
    Ziqi Yue et al, 2024, Animals CrossRef
56. Afatinib Combined with Bevacizumab in the Treatment of Patients with Non-Small Cell Lung Cancer Harboring EGFR G719X, S768I or L861Q/P Mutations
    Xiang Han et al, 2024, IJGM CrossRef
57. ATP_mCNN: Predicting ATP binding sites through pretrained language models and multi-window neural networks
    Van-The Le et al, 2025, Computers in Biology and Medicine CrossRef
58. Cost-effectiveness of lazertinib as first-line treatment in patients with EGFR-mutated advanced lung cancer
    Li-Jung Elizabeth Ku et al, 2025, Ther Adv Med Oncol CrossRef